​

Arcus Biosciences (RCUS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Arcus Biosciences Revenue Highlights

Latest Revenue (Y)

$247.00M

Latest Revenue (Q)

$17.00M

Main Segment (Y)

License And Development Services

Arcus Biosciences Revenue by Period

Arcus Biosciences Revenue by Year

DateRevenueChange
2025-12-31$247.00M-4.26%
2024-12-31$258.00M120.51%
2023-12-31$117.00M4.46%
2022-12-31$112.00M-70.76%
2021-12-31$383.00M391.03%
2020-12-31$78.00M420.00%
2019-12-31$15.00M79.58%
2018-12-31$8.35M491.15%
2017-12-31$1.41M100.00%
2016-12-31--

Arcus Biosciences generated $247.00M in revenue during NA 2025, up -4.26% compared to the previous quarter, and up 316.67% compared to the same period a year ago.

Arcus Biosciences Revenue by Quarter

DateRevenueChange
2026-03-31$17.00M-48.48%
2025-12-31$33.00M26.92%
2025-09-30$26.00M-83.75%
2025-06-30$160.00M471.43%
2025-03-31$28.00M7.69%
2024-12-31$26.00M-45.83%
2024-09-30$48.00M23.08%
2024-06-30$39.00M-73.10%
2024-03-31$145.00M367.74%
2023-12-31$31.00M-3.13%
2023-09-30$32.00M10.34%
2023-06-30$29.00M16.00%
2023-03-31$25.00M-25.72%
2022-12-31$33.66M1.98%
2022-09-30$33.00M22.22%
2022-06-30$27.00M50.00%
2022-03-31$18.00M-94.92%
2021-12-31$354.50M3646.95%
2021-09-30$9.46M-
2021-06-30$9.46M-
2021-03-31$9.46M-0.27%
2020-12-31$9.49M-85.30%
2020-09-30$64.53M3587.43%
2020-06-30$1.75M-
2020-03-31$1.75M-82.05%
2019-12-31$9.75M457.14%
2019-09-30$1.75M-
2019-06-30$1.75M-
2019-03-31$1.75M12.04%
2018-12-31$1.56M-63.60%
2018-09-30$4.29M243.28%
2018-06-30$1.25M-
2018-03-31$1.25M-
2017-12-31$1.25M666.87%
2017-09-30$163.00K100.00%
2017-06-30-100.00%
2017-03-31--

Arcus Biosciences generated $17.00M in revenue during Q1 2026, up -48.48% compared to the previous quarter, and up 65.38% compared to the same period a year ago.

Arcus Biosciences Revenue Breakdown

Arcus Biosciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
License And Development Services$221.00M----
License$7.00M----
R&D Services$8.00M----
Development Services$17.00M----
Other Collaboration Revenue-$36.00M$37.00M$33.00M-
License and Development Services Revenue---$74.00M-
Gilead Access Rights----$30.91M
Development Services for all Gilead Programs----$1.14M
Taiho Access Rights----$7.00M
Taiho License to Domvanalimab----$15.00M
Gilead License to Domvanalimab----$328.84M

Arcus Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 25: License And Development Services (87.35%), Development Services (6.72%), R&D Services (3.16%), and License (2.77%).

Quarterly Revenue by Product

Product/ServiceMar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Other Collaboration Revenue$5.00M$8.00M$19.00M$7.00M$10.00M$9.00M$10.00M$10.00M$8.00M$8.05M----------
License And Development Services$12.00M-------------------
R&D Services--$17.00M$17.00M----------------
License And R&D Services--$192.00M$192.00M----------------
License and Development Services Revenue----$20.00M$41.00M$135.00M$22.00M$19.00M$17.00M$25.63M---------
License and Development Services for All Gilead Programs-------------$23.74M$16.69M$7.94M----
Taiho Access Rights-------------$1.52M$1.75M$1.75M----
Gilead Access Rights-------------$8.32M$8.32M$8.32M$7.78M$7.71M$7.71M-
License--------------------
Collaboration-----------------$7.71M--
Taiho Collaboration Agreement------------------$1.75M$1.75M

Arcus Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: License And Development Services (70.59%), and Other Collaboration Revenue (29.41%).

Arcus Biosciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RCUSArcus Biosciences$247.00M$17.00M
GLPGGalapagos$239.70M$62.43M
LQDALiquidia$158.32M$132.87M
IBRXImmunityBio$113.29M$44.21M
VRDNViridian Therapeutics$70.85M$141.00K
AGIOAgios Pharmaceuticals$54.03M$20.75M
OCULOcular Therapeutix$51.82M$10.79M
COGTCogent Biosciences--
BEAMBeam Therapeutics--
DNLIDenali Therapeutics--

RCUS Revenue FAQ

What is Arcus Biosciences’s yearly revenue?

Arcus Biosciences's yearly revenue for 2025 was $247M, representing a decrease of -4.26% compared to 2024. The company's yearly revenue for 2024 was $258M, representing an increase of 120.51% compared to 2023. RCUS's yearly revenue for 2023 was $117M, representing an increase of 4.46% compared to 2022.

What is Arcus Biosciences’s quarterly revenue?

Arcus Biosciences's quarterly revenue for Q1 2026 was $17M, a -48.48% decrease from the previous quarter (Q4 2025), and a -39.29% decrease year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $33M, a 26.92% increase from the previous quarter (Q3 2025), and a 26.92% increase year-over-year (Q4 2024). RCUS's quarterly revenue for Q3 2025 was $26M, a -83.75% decrease from the previous quarter (Q2 2025), and a -45.83% decrease year-over-year (Q3 2024).

What is Arcus Biosciences’s revenue growth rate?

Arcus Biosciences's revenue growth rate for the last 3 years (2023-2025) was 111.11%, and for the last 5 years (2021-2025) was -35.51%.

What are Arcus Biosciences’s revenue streams?

Arcus Biosciences's revenue streams in c 25 are License And Development Services, License, R&D Services, and Development Services. License And Development Services generated $221M in revenue, accounting 87.35% of the company's total revenue License generated $7M in revenue, accounting 2.77% of the company's total revenue R&D Services generated $8M in revenue, accounting 3.16% of the company's total revenue Development Services generated $17M in revenue, accounting 6.72% of the company's total revenue

What is Arcus Biosciences’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Arcus Biosciences was License And Development Services. This segment made a revenue of $221M, representing 87.35% of the company's total revenue.